Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.24
CRIS's Cash-to-Debt is ranked lower than
71% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CRIS: 2.24 )
Ranked among companies with meaningful Cash-to-Debt only.
CRIS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.76  Med: 7.4 Max: No Debt
Current: 2.24
Equity-to-Asset 0.51
CRIS's Equity-to-Asset is ranked lower than
67% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CRIS: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
CRIS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.7 Max: 0.93
Current: 0.51
0.3
0.93
Piotroski F-Score: 3
Altman Z-Score: -15.33
Beneish M-Score: -4.26
WACC vs ROIC
22.13%
-1009.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -771.08
CRIS's Operating Margin % is ranked lower than
74% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. CRIS: -771.08 )
Ranked among companies with meaningful Operating Margin % only.
CRIS' s Operating Margin % Range Over the Past 10 Years
Min: -771.08  Med: -113.33 Max: -35.24
Current: -771.08
-771.08
-35.24
Net Margin % -802.58
CRIS's Net Margin % is ranked lower than
76% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. CRIS: -802.58 )
Ranked among companies with meaningful Net Margin % only.
CRIS' s Net Margin % Range Over the Past 10 Years
Min: -802.59  Med: -105.54 Max: -27.72
Current: -802.58
-802.59
-27.72
ROE % -129.21
CRIS's ROE % is ranked lower than
85% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. CRIS: -129.21 )
Ranked among companies with meaningful ROE % only.
CRIS' s ROE % Range Over the Past 10 Years
Min: -129.21  Med: -29.93 Max: -11.29
Current: -129.21
-129.21
-11.29
ROA % -79.84
CRIS's ROA % is ranked lower than
79% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. CRIS: -79.84 )
Ranked among companies with meaningful ROA % only.
CRIS' s ROA % Range Over the Past 10 Years
Min: -79.84  Med: -25.84 Max: -10.23
Current: -79.84
-79.84
-10.23
ROC (Joel Greenblatt) % -14915.63
CRIS's ROC (Joel Greenblatt) % is ranked lower than
90% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. CRIS: -14915.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRIS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -16681.33  Med: -2262.58 Max: -240.25
Current: -14915.63
-16681.33
-240.25
3-Year Revenue Growth Rate -32.10
CRIS's 3-Year Revenue Growth Rate is ranked lower than
78% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CRIS: -32.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRIS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: -0.3 Max: 76.3
Current: -32.1
-39.7
76.3
3-Year EBITDA Growth Rate 63.30
CRIS's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CRIS: 63.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRIS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.4  Med: -9.1 Max: 63.3
Current: 63.3
-49.4
63.3
3-Year EPS without NRI Growth Rate 44.20
CRIS's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CRIS: 44.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRIS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.5  Med: -11.9 Max: 44.2
Current: 44.2
-74.5
44.2
GuruFocus has detected 4 Warning Signs with Curis Inc $CRIS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CRIS Guru Trades in Q1 2016

First Eagle Investment 24,008,672 sh (unchged)
Paul Tudor Jones 18,963 sh (unchged)
Steven Cohen 1,100,000 sh (-7.79%)
Jim Simons 38,700 sh (-57.14%)
» More
Q2 2016

CRIS Guru Trades in Q2 2016

Jim Simons 39,400 sh (+1.81%)
Steven Cohen 1,100,000 sh (unchged)
Paul Tudor Jones 18,963 sh (unchged)
First Eagle Investment 24,008,672 sh (unchged)
» More
Q3 2016

CRIS Guru Trades in Q3 2016

Jim Simons 143,300 sh (+263.71%)
Steven Cohen 1,100,200 sh (+0.02%)
First Eagle Investment 24,008,672 sh (unchged)
Paul Tudor Jones 18,963 sh (unchged)
» More
Q4 2016

CRIS Guru Trades in Q4 2016

Jim Simons 361,100 sh (+151.99%)
First Eagle Investment 24,008,672 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CRIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CLDX, OTCPK:ABVC, NAS:MACK, NAS:PACB, NAS:CARA, NAS:AGEN, NAS:CRVS, NAS:NSTG, NAS:CERS, NAS:OTIC, NAS:AUPH, NAS:TLGT, NAS:BSTC, NAS:PRTK, AMEX:BTX, OTCPK:SNBIF, NAS:AVDL, NAS:OMER, NAS:MYOK, NAS:INO » details
Traded in other countries:CUS.Germany,
Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers. Its products include CUDC-907, phosphatidylinositol-3-kinase and small molecule inhibitor of histone deacetylase.

Curis is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, breast cancers, and others.

Ratios

vs
industry
vs
history
PB Ratio 14.30
CRIS's PB Ratio is ranked lower than
90% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CRIS: 14.30 )
Ranked among companies with meaningful PB Ratio only.
CRIS' s PB Ratio Range Over the Past 10 Years
Min: 1.15  Med: 4.26 Max: 16.28
Current: 14.3
1.15
16.28
PS Ratio 51.95
CRIS's PS Ratio is ranked lower than
75% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. CRIS: 51.95 )
Ranked among companies with meaningful PS Ratio only.
CRIS' s PS Ratio Range Over the Past 10 Years
Min: 2.4  Med: 14.33 Max: 382
Current: 51.95
2.4
382
EV-to-EBIT -6.84
CRIS's EV-to-EBIT is ranked lower than
99.99% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. CRIS: -6.84 )
Ranked among companies with meaningful EV-to-EBIT only.
CRIS' s EV-to-EBIT Range Over the Past 10 Years
Min: -674  Med: -8.45 Max: -0.5
Current: -6.84
-674
-0.5
EV-to-EBITDA -6.89
CRIS's EV-to-EBITDA is ranked lower than
99.99% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. CRIS: -6.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRIS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1088.8  Med: -9.05 Max: -0.6
Current: -6.89
-1088.8
-0.6
Current Ratio 3.56
CRIS's Current Ratio is ranked lower than
54% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CRIS: 3.56 )
Ranked among companies with meaningful Current Ratio only.
CRIS' s Current Ratio Range Over the Past 10 Years
Min: 3.56  Med: 7.95 Max: 14.29
Current: 3.56
3.56
14.29
Quick Ratio 3.56
CRIS's Quick Ratio is ranked lower than
52% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CRIS: 3.56 )
Ranked among companies with meaningful Quick Ratio only.
CRIS' s Quick Ratio Range Over the Past 10 Years
Min: 3.56  Med: 7.95 Max: 14.29
Current: 3.56
3.56
14.29
Days Sales Outstanding 119.24
CRIS's Days Sales Outstanding is ranked lower than
77% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. CRIS: 119.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRIS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.04  Med: 20.73 Max: 119.24
Current: 119.24
1.04
119.24
Days Payable 5.00
CRIS's Days Payable is ranked lower than
92% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 59.13 vs. CRIS: 5.00 )
Ranked among companies with meaningful Days Payable only.
CRIS' s Days Payable Range Over the Past 10 Years
Min: 5  Med: 3791.15 Max: 5381.69
Current: 5
5
5381.69

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.00
CRIS's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CRIS: -18.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRIS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43.8  Med: -8.9 Max: -3.7
Current: -18
-43.8
-3.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 26.91
CRIS's Price-to-Net-Cash is ranked lower than
87% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. CRIS: 26.91 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRIS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.78  Med: 8.22 Max: 28
Current: 26.91
1.78
28
Price-to-Net-Current-Asset-Value 21.14
CRIS's Price-to-Net-Current-Asset-Value is ranked lower than
87% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CRIS: 21.14 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRIS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.78  Med: 7.63 Max: 22
Current: 21.14
1.78
22
Price-to-Tangible-Book 21.14
CRIS's Price-to-Tangible-Book is ranked lower than
90% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CRIS: 21.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRIS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.64  Med: 6.2 Max: 21.43
Current: 21.14
1.64
21.43
Price-to-Median-PS-Value 3.61
CRIS's Price-to-Median-PS-Value is ranked lower than
89% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. CRIS: 3.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRIS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 1.15 Max: 11.45
Current: 3.61
0.13
11.45
Earnings Yield (Greenblatt) % -14.59
CRIS's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. CRIS: -14.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRIS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -20.86  Med: 0.8 Max: 1.1
Current: -14.59
-20.86
1.1

More Statistics

Revenue (TTM) (Mil) $7.53
EPS (TTM) $ -0.44
Beta2.68
Short Percentage of Float2.02%
52-Week Range $1.42 - 3.72
Shares Outstanding (Mil)141.89

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8 7 7
EPS ($) -0.47 -0.46 -0.43
EPS without NRI ($) -0.47 -0.46 -0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CRIS

Headlines

Articles On GuruFocus.com
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
First Eagle Increases Holdings of Spin-Off and Cancer Drug Company Mar 10 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
What the Gurus Did This Week - Weekly Update on Guru Real Time Activity Jun 14 2013 
Weekly CFO Sells Highlight: USB, GNC, WWWW, GWRE, CRIS, CSL Apr 30 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 
Curis Inc. Reports Operating Results (10-Q) Aug 03 2010 
Jean-Marie Eveillard Buys More Curis Inc. Aug 11 2009 
Curis Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Curis, Inc. :CRIS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference Mar 16 2017
Curis, Inc. :CRIS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
CURIS INC Financials Mar 14 2017
Markets Rally Late to Close in the Green: Today's Research Reports on Stocks to Watch Curis and... Mar 10 2017
Curis, Inc. breached its 50 day moving average in a Bullish Manner : CRIS-US : March 10, 2017 Mar 10 2017
Edited Transcript of CRIS earnings conference call or presentation 9-Mar-17 1:30pm GMT Mar 09 2017
Biotech Premarket Movers: Spectrum, BioCryst, Curis Mar 09 2017
Curis Inc Earnings Call scheduled for 8:30 am ET today Mar 09 2017
Curis reports 4Q loss Mar 09 2017
Curis reports 4Q loss Mar 09 2017
CURIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 09 2017
Q4 2016 Curis Inc Earnings Release - Before Market Open Mar 09 2017
Curis Reports Fourth Quarter and Year-End 2016 Financial Results Mar 09 2017
Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on... Mar 07 2017
Curis to Present at the Cowen and Company 37th Annual Health Care Conference Mar 01 2017
Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference Feb 17 2017
Curis, Inc. – Value Analysis (NASDAQ:CRIS) : January 13, 2017 Jan 13 2017
Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : January 12, 2017 Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)